Tag: LSD

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug ...

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...

A new analysis of brain activity under LSD suggests the psychedelic state involves a more complicated reorganisation of neural rhythms ...

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...

Australia's modern psychedelic medicine story is usually traced to the Therapeutic Goods Administration's 2023 decision to allow authorised psychiatrists to ...

The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes ...

Definium Therapeutics has reported positive Phase III results for its LSD-based medicine DT120 in generalised anxiety disorder, giving the company ...

LSD has moved a significant step closer to becoming an approved prescription medicine after Definium Therapeutics reported positive topline results ...

The modern psychedelic renaissance is often framed through the lens of clinical legitimacy. Today, psilocybin is being studied at world-leading ...

LSD occupies a uniquely complicated position in the history of psychedelic medicine. Few compounds have had such an outsized influence ...